UNSPSC 51182106: Terlipressin

This classification denotes an antidiurectic hormone analogue, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Z5X49W53P. European Medicines Agency schedules Terlipressin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10927MIG. Terlipressin generally arises in the molecular formula C52H74N16O15S2. The term TERLIPRESSIN is an International Non-Proprietary Name or INN. TERLIPRESSIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

UNSPSC 51182106 Terlipressin, a Commodity code, encompasses pharmaceutical procurement by state and local health systems and correctional facilities through cooperative purchasing vehicles. State and local governments source terlipressin and related injectable vasoactive pharmaceuticals as part of broader generic multi-source drug procurement programs that consolidate purchasing across multiple jurisdictions to achieve volume discounts and standardized supply-chain management. The work involves vendors certifying cGMP and Drug Supply Chain Security Act compliance, maintaining relationships with authorized pharmaceutical wholesalers, and delivering products through established chargeback systems with tiered pricing options including flat-price, net-price, and WAC-minus structures. Issuing bodies include state departments of administration and health, operating through multistate cooperative purchasing alliances that aggregate demand across participating states and subordinate government facilities such as hospitals, prisons, and clinics.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon. The solicitation requires vendors to supply comprehensive NDC-coded product inventories through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC—with products available by May 15, 2026 and awarded agreements effective July 1, 2026. Evaluation prioritizes price competitiveness (75 percent weight), with secondary criteria including fixed pricing structure (10 percent), EDI capability (5 percent), administrative fee compliance (5 percent), and data format adherence (5 percent). Contract term is two years for new vendors with optional extensions, and vendors must carry commercial general liability insurance of $5 million per occurrence and network security liability of $2 million. The RFP does not identify specific set-aside designations in available documentation.